Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Metformin for Olanzapine-Induced Metabolic Disturbance
NCT06326840Completed
- Sponsor
- Taipei Medical University Hospital
- Start
- May 2010
- Primary completion
- Jun 2011
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Open-label, single-arm trial of metformin in metabolic disorder and hyperprolactinemia, sponsored by Taipei Medical University Hospital. Primary endpoints: Glucose level at 8 weeks, Prolactin level at 8 weeks and 6 more. Started May 2010; status: completed.
02
Drugs
metformin
03
Conditions
metabolic disorderhyperprolactinemia
Beyond the preview
Go deeper on NCT06326840.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06326840.